IRs (95% CI) of AEs and SAEs (all cause)
| RA (N=7964) | PsA (N=783) | UC (N=1157) | PsO (N=3663) | |
| Total tofacitinib exposure, patient-years | 23 497 | 2038 | 2581 | 8950 |
| Median exposure, years | 2.1 | 3.0 | 1.7 | 2.4 |
| Discontinuations due to AEs, IR (95% CI) (n) | 7.2 (6.9 to 7.6) (1705) | 3.8 (3.0 to 4.8) (80) | 4.1 (3.3 to 4.9) (108) | 5.7 (5.3 to 6.3) (530) |
| SAEs,* IR (95% CI) (n) | 9.0 (8.6 to 9.4) (1913) | 7.0 (5.8 to 8.2) (135) | 8.5 (7.4 to 9.8) (210) | 5.5 (5.0 to 6.0) (484) |
| Mortality,* IR (95% CI) (n) | 0.2 (0.2 to 0.3) (59) | 0.1 (0.0 to 0.3) (2) | 0.1 (0.0 to 0.3) (2) | 0.2 (0.1 to 0.3) (17) |
*Within 28 days of the last dose of study drug.
AE, adverse event; IR, incidence rate (unique patients with events per 100 patient-years); n, unique number of patients with event; N, number of patients in the disease cohort; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; SAE, serious adverse event; UC, ulcerative colitis.